Eikon Therapeutics, Inc. Common Stock (EIKN) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.0x

Market Cap

$587.15M

MomentumView details →

1D Return

−1.09%

YTD Return

—

RSI (14)

50.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.0x

Market Cap

$587.15M

RSI (14)

50.3

MomentumView details →

1D Return

−1.09%

YTD Return

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−69.51%

ROA (TTM)

−41.59%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−$1.63

EPS Surprise

−3.16%

Beats (12Q)

0/12

Next Q EPS Est

−$1.64

Avg Surprise (4Q)

−28.46%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.54x

Current Ratio

9.89x

Quick Ratio

9.89x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsNov 12, 2026 →

Latest newsMore news →

Eikon Therapeutics reported its financial results for the second quarter of 2026 and provided clinical program updates on August 13, 2026.22d ago

Ma. Fatima D. Francisco was appointed as a Class I director and member of the Compensation Committee of Eikon Therapeutics, Inc., effective June 15, 2026, with an option to purchase 85,937 shares of common stock at $8.96 per share vesting in 48 equal monthly installments.87d ago

Similar companies

REGENXBIO Inc.RGNX Zura Bio LimitedZURA Tectonic Therapeutic, Inc.TECX Cabaletta Bio, Inc.CABA Autolus Therapeutics plcAUTL 3D Medicines Inc.01244.HK Find similar companies →

Latest newsMore news →

Eikon Therapeutics reported its financial results for the second quarter of 2026 and provided clinical program updates on August 13, 2026.22d ago Ma. Fatima D. Francisco was appointed as a Class I director and member of the Compensation Committee of Eikon Therapeutics, Inc., effective June 15, 2026, with an option to purchase 85,937 shares of common stock at $8.96 per share vesting in 48 equal monthly installments.87d ago